Centro Cardiologico Monzino
cardiologicomonzino.itTotal trials
65
Active
18
Phase 3
2
Total enrollment
69,005
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Atorvastatin 80 mg/day | — | — | — | — | — | 1 |
Next readouts
- 2026-11-30
Top conditions
- Heart Failure9
- Coronary Artery Disease5
- Cardiopulmonary Exercise Test3
- Atrial Fibrillation3
- Cardiovascular Diseases3
- Myocardial Ischemia2
- Mitral Valve Prolapse2
- Depression2
Frequently asked questions about Centro Cardiologico Monzino
- How many clinical trials does Centro Cardiologico Monzino have on ClinicalTrials.gov?
- Centro Cardiologico Monzino is listed as the lead sponsor on 65 clinical trials in ClinicalTrials.gov, 18 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Centro Cardiologico Monzino's trials are in Phase 3?
- 2 of Centro Cardiologico Monzino's trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does Centro Cardiologico Monzino focus on?
- Centro Cardiologico Monzino's most-studied conditions on ClinicalTrials.gov are Heart Failure, Coronary Artery Disease, Cardiopulmonary Exercise Test, Atrial Fibrillation, Cardiovascular Diseases.
- When are Centro Cardiologico Monzino's next clinical trial readouts?
- Centro Cardiologico Monzino has 1 upcoming primary-completion readout tracked here; the soonest is “Statin Effect on Arrhythmogenic Cardiomyopathy Disease Progression (SEARCH)”, expected around 2026-11-30.